Sangamo Therapeutics (SGMOQ) Depreciation & Amortization (CF) (2010 - 2025)

Sangamo Therapeutics' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $998000.0 for Q4 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 19.58% year-over-year to $998000.0 in Q4 2025; TTM through Dec 2025 was $4.0 million, a 21.68% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 21.68% from the prior year.
• Depreciation & Amortization (CF) advanced to $998000.0 in Q4 2025 per SGMOQ's latest filing, from $989000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.5 million in Q3 2023 and bottomed at $989000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $2.1 million (2021), against an average of $2.3 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 87.87% in 2021 and sank 77.83% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.7 million in 2021, then climbed by 22.68% to $3.3 million in 2022, then plunged by 44.3% to $1.9 million in 2023, then tumbled by 33.35% to $1.2 million in 2024, then retreated by 19.58% to $998000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Depreciation & Amortization (CF) figures stand at $998000.0 (Q4 2025), $989000.0 (Q3 2025), and $993000.0 (Q2 2025).